Video index

1. Call to order, logistical announcements, and roll call

2. Consideration of draft meeting minutes for March 18, 2026, meeting

3. TPI staff updates and recommendations on the implementation of the TPI enabling statute including presentation, possible action and discussion of activity pursuant to and in development of the TPI Business Plan, including related work by and through contracted vendors and consideration of state agency, stakeholder, and federal activities that may impact TPI's statutory mission or functions, including but not limited to: a. Preliminary and/or forthcoming insights and/or results, subject to further analysis and validation, based on the work related to pharmacy benefit contract reviews, data analytics, clinical research, and market research; b. Update on Request for Information (RFI), HHS0017013, RFI TPI Direct-to-Manufacturer Prescriptions; and c. Revised business plan due no later than June 1, 2026, pursuant to Texas Government Code, Section 2177.006, including recommendations for best practices and other TPI Board recommendations on continuation of the initiative

4. Texas Pharmaceutical Initiative Advisory Council (TPIAC) members and other covered agency representatives have been invited to advise and engage in discussions with the TPI Board on matters and activities (see Texas Government Code, Section 2177.008, in general): a. Pertaining to the implementation of the TPI Business Plan; b. Updates on member and covered agencies' activities pertinent to procurement and/or management of pharmaceuticals; and c. On carrying out the duties imposed on the TPI Board

Items 5 & 6

8. Review of action items from the current meeting, discussion of agenda items for future meetings, pending informational requests or action items from prior meetings, and important dates

Apr 22, 2026 Texas Pharmaceutical Initiative Board

Full agenda
Share this video

1. Call to order, logistical announcements, and roll call

2. Consideration of draft meeting minutes for March 18, 2026, meeting

3. TPI staff updates and recommendations on the implementation of the TPI enabling statute including presentation, possible action and discussion of activity pursuant to and in development of the TPI Business Plan, including related work by and through contracted vendors and consideration of state agency, stakeholder, and federal activities that may impact TPI's statutory mission or functions, including but not limited to: a. Preliminary and/or forthcoming insights and/or results, subject to further analysis and validation, based on the work related to pharmacy benefit contract reviews, data analytics, clinical research, and market research; b. Update on Request for Information (RFI), HHS0017013, RFI TPI Direct-to-Manufacturer Prescriptions; and c. Revised business plan due no later than June 1, 2026, pursuant to Texas Government Code, Section 2177.006, including recommendations for best practices and other TPI Board recommendations on continuation of the initiative

4. Texas Pharmaceutical Initiative Advisory Council (TPIAC) members and other covered agency representatives have been invited to advise and engage in discussions with the TPI Board on matters and activities (see Texas Government Code, Section 2177.008, in general): a. Pertaining to the implementation of the TPI Business Plan; b. Updates on member and covered agencies' activities pertinent to procurement and/or management of pharmaceuticals; and c. On carrying out the duties imposed on the TPI Board

Items 5 & 6

8. Review of action items from the current meeting, discussion of agenda items for future meetings, pending informational requests or action items from prior meetings, and important dates

© 2003-2026 Swagit Productions, LLC